Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message

Login Alert

Cancel
Log in
×
×
Register
Log In
(0) Cart
Logo for Cambridge Core from Cambridge University Press. Click to return to homepage.
Logo for Cambridge Core from Cambridge University Press. Click to return to homepage.
Cited by
  • Crossref logo 13
  • Google Scholar logo
Crossref Citations
Crossref logo
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Khanna, Sahil Assi, Maha Lee, Christine Yoho, David Louie, Thomas Knapple, Whitfield Aguilar, Humberto Garcia-Diaz, Julia Wang, Gary P. Berry, Scott M. Marion, Joe Su, Xin Braun, Tricia Bancke, Lindy and Feuerstadt, Paul 2022. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs, Vol. 82, Issue. 15, p. 1527.
  • CrossRef
  • Google Scholar
Lee, Christine Louie, Thomas Bancke, Lindy Guthmueller, Beth Harvey, Adam Feuerstadt, Paul Khanna, Sahil Orenstein, Robert and Dubberke, Erik R. 2023. Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therapeutic Advances in Gastroenterology, Vol. 16, Issue. ,
  • CrossRef
  • Google Scholar
Chopra, Teena Hecht, Gail and Tillotson, Glenn 2023. Gut microbiota and microbiota-based therapies for Clostridioides difficile infection. Frontiers in Medicine, Vol. 9, Issue. ,
  • CrossRef
  • Google Scholar
Dubberke, Erik R. Orenstein, Robert Khanna, Sahil Guthmueller, Beth and Lee, Christine 2023. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. Infectious Diseases and Therapy, Vol. 12, Issue. 2, p. 703.
  • CrossRef
  • Google Scholar
Schönherr, Sebastian Jung, Laura and Lübbert, Christoph 2023. Clostridioides difficile – Neue Erkenntnisse und Therapieempfehlungen. DMW - Deutsche Medizinische Wochenschrift, Vol. 148, Issue. 12, p. 752.
  • CrossRef
  • Google Scholar
Reveles, Kelly R. Yang, Min Garcia-Horton, Viviana Edwards, Marie Louise Guo, Amy Lodise, Thomas Bochan, Markian Tillotson, Glenn and Dubberke, Erik R. 2023. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis. Advances in Therapy, Vol. 40, Issue. 7, p. 3104.
  • CrossRef
  • Google Scholar
Orenstein, Robert 2023. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660. Infectious Diseases and Therapy, Vol. 12, Issue. 1, p. 1.
  • CrossRef
  • Google Scholar
Feuerstadt, Paul Allegretti, Jessica R. Dubberke, Erik R. Guo, Amy Harvey, Adam Yang, Min Garcia-Horton, Viviana Fillbrunn, Mirko Tillotson, Glenn Bancke, Lindy L. LaPlante, Kerry Garey, Kevin W. and Khanna, Sahil 2024. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious Diseases and Therapy, Vol. 13, Issue. 1, p. 221.
  • CrossRef
  • Google Scholar
Cotto, Candace Baker, Kathy Fallon, Echo and Rimon, Sharon 2024. Fecal Microbiota, Live-jslm (RBL; REBYOTA®) for Prevention of Recurrent Clostridioides difficile Infection: What Gastroenterology Nurses Need to Know. Gastroenterology Nursing, Vol. 47, Issue. 5, p. 378.
  • CrossRef
  • Google Scholar
Monday, Lea Tillotson, Glenn and Chopra, Teena 2024. Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details. Infection and Drug Resistance, Vol. Volume 17, Issue. , p. 623.
  • CrossRef
  • Google Scholar
Garcia, Mary Castex, Julie Duhaime, Erin and Monk, Miranda 2024. Fecal Microbiota, Live-jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection. The Journal for Nurse Practitioners, Vol. 20, Issue. 10, p. 105195.
  • CrossRef
  • Google Scholar
Reveles, Kelly R Gonzales-Luna, Anne J Golan, Yoav Alonso, Carolyn D Guthmueller, Beth Tan, Xing Bidell, Monique R Pokhilko, Victoria Crawford, Carl V and Skinner, Andrew M 2024. Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study. Open Forum Infectious Diseases, Vol. 11, Issue. 7,
  • CrossRef
  • Google Scholar
Menon, Rajita Bhattarai, Shakti K. Crossette, Emily Prince, Amanda L. Olle, Bernat Silber, Jeffrey L. Bucci, Vanni Faith, Jeremiah and Norman, Jason M. 2025. Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection. Nature Medicine,
  • CrossRef
  • Google Scholar
Google Scholar Citations

View all Google Scholar citations for this article.

×
Cambridge University Press

Our Site

  • Accessibility
  • Contact & Help
  • Legal Notices

Our Platforms

  • Cambridge Core
  • Cambridge Open Engage
  • Cambridge Higher Education

Our Products

  • Journals
  • Books
  • Elements
  • Textbooks
  • Courseware

Join us online

Please choose a valid location.

  • Rights & Permissions
  • Copyright
  • Privacy Notice
  • Terms of Use
  • Cookies Policy
Cambridge University Press 2025

Cancel
Confirm
×

Save article to Kindle

To send this article to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
  • Volume 2, Issue 1
  • Paul Feuerstadt (a1) (a2), Winnie W. Nelson (a3), Christie Teigland (a4) and David N. Dahdal (a3)
  • DOI: https://doi.org/10.1017/ash.2022.2
Please provide your Kindle email.
Available formats Please select a format to save.
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
  • Volume 2, Issue 1
  • Paul Feuerstadt (a1) (a2), Winnie W. Nelson (a3), Christie Teigland (a4) and David N. Dahdal (a3)
  • DOI: https://doi.org/10.1017/ash.2022.2
Available formats Please select a format to save.
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
  • Volume 2, Issue 1
  • Paul Feuerstadt (a1) (a2), Winnie W. Nelson (a3), Christie Teigland (a4) and David N. Dahdal (a3)
  • DOI: https://doi.org/10.1017/ash.2022.2
Available formats Please select a format to save.
×
×

Reply to: Submit a response

Contents help
Close Contents help

- No HTML tags allowed
- Web page URLs will display as text only
- Lines and paragraphs break automatically
- Attachments, images or tables are not permitted

Please enter your response.

Your details

Email help
Close Email help

Your email address will be used in order to notify you when your comment has been reviewed by the moderator and in case the author(s) of the article or the moderator need to contact you directly.

Please enter a valid email address.
You have entered the maximum number of contributors

Conflicting interests

Do you have any conflicting interests? * Conflicting interests help

Close Conflicting interests help

Please list any fees and grants from, employment by, consultancy for, shared ownership in or any close relationship with, at any time over the preceding 36 months, any organisation whose interests may be affected by the publication of the response. Please also list any non-financial associations or interests (personal, professional, political, institutional, religious or other) that a reasonable reader would want to know about in relation to the submitted work. This pertains to all the authors of the piece, their spouses or partners.